disitamab vedotin + toripalimab + carboplatin

This is a **combination regimen** consisting of disitamab vedotin, toripalimab, and carboplatin, with clinical evaluation primarily in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma. **Disitamab vedotin (RC48, Aidixi)** is an antibody-drug conjugate (ADC) targeting HER2, delivering a cytotoxic payload to HER2-expressing tumor cells. **Toripalimab (JS001, Loqtorzi, Tuoyi)** is a monoclonal antibody anti-PD-1 immune checkpoint inhibitor that blocks the interaction between PD-1 and its ligands, potentiating T-cell-based immune responses against cancer. **Carboplatin** is a small molecule platinum-based DNA crosslinking agent (alkylating-like agent, antineoplastic) commonly used in chemotherapeutic regimens to induce apoptosis in rapidly dividing tumor cells. This combination is under investigation for its survival benefit, durable disease control and manageable safety in HER2-expressing urothelial carcinoma, particularly as a first-line regimen in patients regardless of cisplatin eligibility or specific HER2 expression level. Disitamab vedotin + toripalimab combination has been highlighted for statistically significant improvements in progression-free and overall survival compared to standard chemotherapy in phase 3 trials. The triple combination with carboplatin represents a chemotherapy-immunotherapy-targeted therapy regimen.

Brand names

Tuoyi